XML 61 R49.htm IDEA: XBRL DOCUMENT
v3.26.1

Revenue from contracts with customers (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2026
Revenue [abstract] |
Disclosures about major customers and credit risk | The table below sets forth net sales for the six months ended June 30, 2026 and June 30, 2025
(€ million) | Europe | United States | Other countries | June 30, 2026 | Europe | United States | Other countries | June 30, 2025 |  |  |  |
Total Group | 4,304 |  | 11,633 |  | 6,169 |  | 22,106 |  | 4,144 |  | 9,535 |  | 6,210 |  | 19,889 |  |  |  |  |
Immunology |  |  |  |  |  |  |  |  |  |  |  |
of which | Dupixent | 1,146 |  | 6,922 |  | 1,256 |  | 9,324 |  | 944 |  | 5,283 |  | 1,085 |  | 7,312 |  |  |  |  |
Rare diseases |  |  |  |  |  |  |  |  |  |  |  |
of which | ALTUVIIIO | — |  | 576 |  | 98 |  | 674 |  | — |  | 456 |  | 86 |  | 542 |  |  |  |  |
| Fabrazyme | 138 |  | 256 |  | 129 |  | 523 |  | 134 |  | 261 |  | 130 |  | 525 |  |  |  |  |
| Nexviazyme/Nexviadyme | 152 |  | 211 |  | 63 |  | 426 |  | 132 |  | 195 |  | 60 |  | 387 |  |  |  |  |
| Cerezyme | 126 |  | 86 |  | 140 |  | 352 |  | 119 |  | 91 |  | 153 |  | 363 |  |  |  |  |
| Ayvakit | 44 |  | 322 |  | 1 |  | 367 |  | — |  | — |  | — |  | — |  |  |  |  |
Oncology |  |  |  |  |  |  |  |  |  |  |  |
of which | Sarclisa | 108 |  | 132 |  | 114 |  | 354 |  | 83 |  | 119 |  | 74 |  | 276 |  |  |  |  |
Other medicines |  |  |  |  |  |  |  |  |  |  |  |
of which | Lantus | 146 |  | 344 |  | 323 |  | 813 |  | 149 |  | 395 |  | 332 |  | 876 |  |  |  |  |
| Toujeo | 259 |  | 134 |  | 336 |  | 729 |  | 248 |  | 126 |  | 318 |  | 692 |  |  |  |  |
| Plavix | 40 |  | 2 |  | 398 |  | 440 |  | 44 |  | 3 |  | 426 |  | 473 |  |  |  |  |
| Lovenox | 202 |  | 5 |  | 157 |  | 364 |  | 247 |  | 9 |  | 191 |  | 447 |  |  |  |  |
| Rezurock | 36 |  | 218 |  | 42 |  | 296 |  | 23 |  | 220 |  | 20 |  | 263 |  |  |  |  |
Industrial sales | 181 |  | 7 |  | 2 |  | 190 |  | 241 |  | 1 |  | 9 |  | 251 |  |  |  |  |
Vaccines |  |  |  |  |  |  |  |  |  |  |  |
of which | Polio/pertussis/Hib primary vaccines and boosters, incl. Heplisav-B | 206 |  | 487 |  | 671 |  | 1,364 |  | 223 |  | 320 |  | 818 |  | 1,361 |  |  |  |  |
| RSV vaccines (Beyfortus) | 87 |  | 65 |  | 240 |  | 392 |  | 85 |  | 68 |  | 203 |  | 356 |  |  |  |  |
| Meningitis, travel and endemics vaccines | 118 |  | 268 |  | 179 |  | 565 |  | 96 |  | 319 |  | 194 |  | 609 |  |  |  |  |
| COVID-19 and Influenza vaccines | 33 |  | 16 |  | 72 |  | 121 |  | 52 |  | 54 |  | 108 |  | 214 |  |  |  |  |
Of which total launches | 546 |  | 1,891 |  | 610 |  | 3,047 |  | 423 |  | 1,204 |  | 473 |  | 2,100 |  |  |  |  |
Disclosure of other revenue |
(€ million) | June 30, 2026 (6 months) | June 30, 2025 (6 months) |
VaxServe sales of non-Sanofi products | 746 |  | 842 |  |
Sales to Opella (a) | 60 |  | 61 |  |
Royalties | 91 |  | 68 |  |
Other(b) | 271 |  | 275 |  |
Total Biopharma Other revenues | 1,168 |  | 1,246 |  |
Sales / Revenues from Opella products(c) | 270 |  | 206 |  |
Total Other revenues | 1,438 |  | 1,452 |  |
(a) Revenues generated from the manufacture of Consumer Healthcare products on behalf of Opella entities. Until April 30, 2025, Opella entities were within the scope of discontinued operations (see Note B.1). With effect from May 1, 2025, Opella entities are treated as related parties in accordance with IAS24 (see Note B.5.). (b) This line mainly comprises revenues received under agreements for Sanofi to provide manufacturing services to third parties. (c) Consumer Healthcare activities not transferred on the effective date of loss of control of Opella. These are primarily

X
- References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2025-01-01 -Paragraph 114 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 103 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_RevenueAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of other revenue [Text Block] + References No definition available. + Details
Name: | sny_DisclosureOfOtherRevenueTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration